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Abbreviations: 
CI Chief Investigator 
CIT Cold ischemic time 
CO Carbon monoxide 
DGF Delayed graft function 
ERI Edinburgh Royal Infirmary  
ESRD End stage renal disease 
HA Heme arginate 
HO-1 Heme-oxygenase 1 
IQR Interquartile range 
IRI Ischaemia reperfusion injury 
KIM-1 Kidney injury marker 1 
NGAL Neutrophil gelatinase-associated lipocalin 
MHRA Medicines and Healthcare products Regulatory Agency (UK drug safety agency) 
PBMC Peripheral blood mononuclear cell 
PCR Polymerase chain reaction 
WIT Warm ischaemic time 
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Abstract  
 
Background:  
The enzyme heme oxygenase-1 (HO-1) degrades heme and protects against ischaemia-reperfusion 
injury (IRI), which is inevitable in transplantation. Monocytes/macrophages (MΦ) are the major 
source of HO-1 and higher levels improve renal transplant outcomes. Heme Arginate (HA) can safely 
induce HO-1 in humans. This randomised controlled trial evaluated the effect of HA on HO-1 
upregulation and renal function in recipients of deceased donor kidneys. 
Methods:  
40 recipients were randomised to either active (3mg kg-1 HA: pre-operatively and day 2) or placebo 
(NaCl: same schedule). Recipient blood was taken daily for peripheral blood mononuclear cells 
(PBMC) extraction. Urine was also collected. Graft biopsies were taken pre-op and day 5. 
Immunosuppression was standard. 
Results:  
HA upregulated PBMC HO-1 protein at 24 hours more than placebo: HA 11.1ng/ml vs. placebo 
0.14ng/ml (p=<0.0001). PBMC HO-1 mRNA was also increased: HA 2.73 fold vs. placebo 1.41 fold 
(p=0.02). HA increased day 5 tissue HO-1 protein immunopositivity compared with placebo: HA 
0.21 vs. placebo -0.03 (p=0.02) and % HO-1 positive renal MΦ also increased: HA 50.8 cells per hpf 
vs. placebo 22.3 (p=0.012). Urinary biomarkers were reduced after HA but not significantly so. 
Histological injury and renal function were similar but the study was not powered to these endpoints. 
Adverse events were equivalent between groups.  
Discussion:  
The primary outcome was achieved and demonstrated for the first time that HA safely induces HO-1 
in renal transplant recipients. Larger studies are planned to determine the impact of HO-1 
upregulation on clinical outcomes and evaluate the benefit to patients at risk of IRI. 
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Introduction 
Renal transplantation is the optimal management for end-stage renal disease (ESRD) because it 
improves quality of life and survival (1). Deceased donor renal transplantation inevitably results in 
ischemia-reperfusion injury (IRI), which is characterised by the production of reactive oxygen free 
radicals, alterations in blood flow, leucocyte infiltration and significant cell dysfunction (2). IRI 
increases the risk of delayed graft function (DGF), necessitating post-transplant dialysis and leading 
to an increased risk of rejection and reduced long-term graft survival (3). Apart from limiting cold 
ischemic time, few methods exist to minimise the effects of IRI. One potential technique is 
preconditioning, using either ischemia or pharmacology (4).  
 
The enzyme heme-oxygenase 1 (HO-1) has emerged as a potential approach to attenuate IRI (5). HO-
1 is the rate-limiting enzyme in heme catabolism and degrades the pro-inflammatory, oxidative free 
heme molecules into biliverdin (further degraded to bilirubin), carbon monoxide (CO) and free 
iron(6). Bilirubin is an anti-oxidant. CO has vasodilatory and anti-apoptotic properties and inhibits a 
number of pro-inflammatory signalling pathways and platelet aggregation. Free iron is sequestered 
by ferritin to limit its toxic effect (7).  
 
Experimental models have shown that following renal IRI, macrophages have roles in both injury 
and repair. They are also the primary HO-1 expressing leucocyte (8). Macrophage infiltration into the 
kidney occurs within 24 hours of IRI and these initial cells have a pro-inflammatory phenotype (M1), 
contributing to various injury processes. As a result, depletion of macrophages at early time-points 
post-IRI protects renal function (9). By contrast, renal macrophages present on days 3-5 following 
IRI have an alternative activation phenotype (M2) and contribute to tissue repair and recovery of 
renal function (9). In a renal IRI model, increased macrophage HO-1 expression was associated with 
reduced injury (10). Improved renal function was also seen after infusion of HO-1 expressing 
macrophages in a similar model (11). Our laboratory has demonstrated in a mouse IRI model that 
heme arginate (HA) pre-conditioning upregulates renal HO-1, principally in interstitial macrophages, 
and results in a significant reduction in subsequent renal injury. This protective effect was lost 
following macrophage depletion (12). Thus, it was hypothesised that amplified HO-1 expression in 
recipient macrophages and renal grafts might reduce IRI and improve outcomes after clinical 
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transplantation. HA, a form of hemin, is suitable for clinical studies, as it has been used safely in the 
treatment of acute porphyria for over 30 years with few reported side effects. In healthy volunteers, 
both hemin and HA have been shown to increase HO-1 concentration in peripheral blood 
mononuclear cells (PBMC) and plasma (13, 14). 
 
The HOT study was a randomised, placebo controlled, blinded, single centre study with the primary 
objective of determining whether pre-treatment of renal transplant recipients with HA upregulated 
HO-1 in PBMCs. Secondary objectives explored the effect of HA on graft tissue, urinary biomarkers 
and renal function.  
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Materials and methods 
All patients on the East of Scotland renal transplant waiting list were informed about the study by 
post before recruitment started. When patients were admitted to Edinburgh Royal Infirmary (ERI) for 
potential deceased donor renal transplant, they were assessed for eligibility.  
A patient was ineligible for inclusion if: 
1. they were unable to receive the standard immunosuppressive regimen  
2. they were unable to give informed consent 
3. they had hypersensitivity reactions to HA  
4. it was a combined transplant or their 3rd or subsequent kidney transplant 
5. they were to be anticoagulated post-operatively or on combined anti-platelet agents due to 
biopsy risks 
 
Study protocol 
This was a single-centre, randomised, blinded, placebo-controlled trial sponsored by ACCORD (a 
joint company from University of Edinburgh and NHS Lothian) and funded by NHS Blood and 
Transplant. The trial protocol was registered at the European Clinical Trials database (EudraCT no: 
2011-004311-23) and ClinicalTrials.gov (NCT01430156) and adhered to the Declaration of Helsinki 
and CONSORT guidelines. The Scottish Regional Ethics Committee and the Medicines and 
Healthcare products Regulatory Agency (MHRA) approved the study (approval number 
2011/R/TR/03 and protocol number HOTstudy_Thomas11). 
 
The sample size calculation was performed on the observed heme oxygenase-1 (HO-1) upregulation 
in cultured human macrophages following HA treatment. Using a two-sided two-sample test with a 
5% level of significance and 80% power, assuming a mean baseline to 24-hour change of 7.47 and a 
common standard deviation of 3.87, the minimum detectable difference in means would be 3.8 with a 
sample size of 17 per group. The final sample size of 20 per group allowed for dropouts.  
 
The randomisation was done by random, random block, with stratification by donor type. The trial 
statistician generated the random allocation sequence and an independent party produced sequentially 
numbered, sealed, opaque envelopes, which were stored securely and only opened by the Chief 
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Investigator (CI) after consent had been given and participant number had been assigned. Subjects 
were randomised to receive either 100ml 0.9% NaCl (placebo) or 3mg kg-1 HA (Normosang, Orphan 
Europe, France) diluted in 100ml 0.9% NaCl. In both groups, participants received the first infusion 
pre-operatively (D0) and this was repeated on day 2 (D2). To ensure maximum post-conditioning 
exposure, the D0 infusion was given as early as possible post-dialysis (if required). All staff (except 
the CI giving the infusion) and participants were blinded.  
 
Prior to infusion, venous blood was taken for PBMC extraction and analysis of baseline HO-1 
expression (D0). Venepuncture was repeated 24 hours after the first infusion (D1) and also on days 2 
(D2, pre-2nd infusion), D3 and D5. Urine was collected on the same days for analysis of KIM-1 and 
NGAL. A needle-biopsy of the graft was taken at the back table (D0) for routine pathology and study 
analysis. A repeat biopsy was requested for all participants on D5. Laboratory samples were analysed 
by the CI after blinding by an independent lab member. All samples were stored in accordance with 
guidelines.  
Otherwise all pre-operative and post-operative care was typical, including standard immunosuppression, 
which comprised of induction therapy with basiliximab, tacrolimus, mycophenolate mofetil (MMF) and 
prednisolone.  
 
HO-1 mRNA and protein levels in PBMCs 
PBMCs were isolated using the previously described Dextran-Percoll method and stored in appropriate 
buffers for subsequent batch analysis of mRNA and protein expression (15). PBMC RNA was extracted 
using the ISOLATE kit (Bioline, UK) and cDNA was synthesised using TaqMan, RT-PCR core kit 
(Invitrogen, USA). The cDNA was analysed in duplicate by quantitative real-time PCR using 
fluorogenic probes for HO-1 and 18s (housekeeping gene) on an ABI Prism 7900 PCR machine 
(Applied Biosystems, USA). For quantification, the threshold cycle of HO-1 (CT) was correlated to the 
constant  expression  of  the  housekeeping  gene;;  ΔCT was defined as CT (HO-1)- CT (18s). The differences 
in expression pre and post infusion were plotted as   ΔΔCT and 2-Δ   Δ   CT calculation was performed to 
determine the fold increase and the two groups were compared.  
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Each sample protein concentration was determined using protein assay (Biorad, USA). All samples were 
standardised to 1mg/ml of total protein and this was analysed in duplicate by the HO-1 ELISA kit to 
determine the amount of HO-1 protein at each time point (ENZO, USA).  
 
Analysis of renal tissue  
The D0 biopsy and D5 biopsy samples were handled and analysed as below: 
x RNA extracted from fresh tissue and analysed in the same manner as PBMC RNA 
x a blinded expert (CB) examined a fixed sample to assess for renal injury using a 13 point system.  
x a fixed section of all the tissue samples underwent immunohistological staining for HO-1 
(ENZO, USA). ImageJ (NIH) was used to quantify the amount of HO-1 protein as percentage of 
total protein.  
x another section of tissue underwent dual immunofluorescence staining for HO-1 (ENZO, USA) 
and CD68 (macrophage marker (Abcam, UK)) and the numbers of dual positive cells were 
counted per high power field.  
 
Urinary biomarkers  
Commercially available ELISA kits from R&D Systems measured urinary KIM-1 and NGAL. KIM-1 
and NGAL values are recorded as a ratio to urinary creatinine to allow for variations in urine 
concentrations.  
 
Clinical outcomes 
Clinical blood results were recorded daily. Need for dialysis, adverse events and urine volumes were 
also recorded. In this study, DGF was determined by change in creatinine in the first week after 
transplantation. Renal function was recorded at day 30 and day 90. 
 
Data and statistical analysis 
The anonymised data was held in a secure, auditable database. PBMC and renal HO-1 expression, 
urine biomarkers and renal macrophage data were not normally distributed; a non-parametric Mann-
Whitney statistical test was used. A comparison of proportions test was used to compare rates of 
DGF between groups. Results are presented as median [IQR] and % values (95% confidence 
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intervals) as appropriate. Statistical analysis was performed on SDSS and graphs created in Prism. A 
p-value of <0.05 was considered statistically significant. 
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Results 
Trial participation 
Patient recruitment began in January 2012 and continued until 40 patients had been randomised in 
May 2013 (Figure 1). Baseline characteristics were similar between the groups (Table 1). No adverse 
reactions and no deaths occurred during the seven-day trial period. There was one graft loss due to 
technical reasons on day seven (placebo group). Acute rejection occurred in one participant in 
placebo group and two in HA group. Five serious adverse events were reported including one ITU 
admission for pulmonary oedema (placebo group), and one further procedure was required in each 
group (placebo: radiological embolization for renal arterio-venous fistula, HA group: nephrectomy 
for graft bleeding). All participants were followed up to 90 days post transplant.  
 
Three potential recipients received the infusion but were not transplanted following back-table 
examination of the kidney at day 0 (D0). All 37 participants who were transplanted provided a blood 
sample at 24 hours (D1) post infusion for primary analysis. One participant in each group refused the 
second infusion and subsequent venepuncture but consented to clinical follow-up. Thus 17 in the 
placebo group and 18 in HA group received both infusions. Five participants in the placebo group 
and three in the HA group declined the day 5 (D5) biopsy and two in each group were not considered 
fit for biopsy. Therefore, there were 25 paired renal tissue samples available for analysis. All 
participants with a transplant in situ at day seven were followed-up. Results are expressed as median 
values with interquartile range [IQR]. 
 
HA upregulated HO-1 in peripheral blood monocytes 
Expressed as the difference in HO-1 expression on D1 compared with D0, HA upregulated HO-1 
concentration by 11.1ng/ml [1.0-37.0], compared with placebo -0.14ng/ml [-0.7-0.3] (p<0.0001, 
Figure 2a). This effect was confirmed with increased expression of HO-1 mRNA: HA treatment 
upregulated HO-1 mRNA expression 2.73 fold [1.8-3.2] compared with placebo 1.41 fold [1.2-2.2] 
(p=0.02, Figure 2b). There was a peak in HO-1 PBMC protein concentration after each HA infusion 
(Figure 2c) but mRNA upregulation did not significantly follow this pattern (Figure 2d).  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 12 
 
HA upregulated HO-1 in renal macrophages 
The number of CD68-positive macrophages per high power field (hpf) was similar between the 
treatment groups at D0 (HA: 3.50 cells per hpf [1.50- 5.25], placebo: 3.00 [2.25- 4.25]) (p=0.956, Figure 
3a). At D5 there were more CD68-positive macrophages in HA group (HA: 7.38 cells per hpf [4.80- 
9.13], placebo: 11.0 [4.5- 25.0]) but this was not significant (p=0.13, Figure 3a). However, there was a 
significant increase in the number of HO-1-positive CD68 macrophages following HA treatment at D5 
(HA: 50.8 cells per hpf [40.0- 59.8], placebo: 22.3 [0.0- 34.8]) (p=0.012, Figure 3b and images Figure 
3c-f). 
 
HA upregulated HO-1 in renal tissue 
There was significant increased expression of renal HO-1 protein in the HA-treated group over time, 
which was not seen with placebo (change in protein expression [D5-D0]: HA: 0.21 [0.1- 0.6], placebo:   
-0.03 [-1.3- 0.1]) (p=0.03, Figure 4a and images 4c-f). HO-1 mRNA expression was not significantly 
affected by HA treatment: HA: 1.68 [0.20- 4.03], placebo 2.02 [0.75- 10.39] (p=0.45, Figure 4b). 
 
HA had limited effect on urinary biomarkers 
There was no significant difference in urinary KIM-1 and NGAL levels between patients treated with 
HA versus placebo at each time point (Figures 5a and 5b). 
 
HA did not alter histological injury or renal function  
There were no significant differences in the severity of tubular injury or necrosis between HA and 
placebo (data not shown). 
There were 12 cases (67%) of DGF in the placebo group and 10 cases (53%) in HA group, a 
difference of 14% (95% CI; -17.2 – 45.3), (p=0.38). When DGF was redefined as dialysis within the 
first seven days post-transplant except for hyperkalaemia, the results were the same. At day 90, there 
was one participant on dialysis in placebo group and none in HA group. There was no improvement 
in creatinine after HA treatment at day 30 and day 90 (data not shown).  
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Discussion 
 
The study achieved its principal objective: pre-treatment of deceased donor renal transplant recipients 
with HA was feasible, safe and well tolerated in immunosuppressed ESRD patients. It also led to 
significant upregulation of HO-1 protein and mRNA in recipient PBMCs. HO-1 is induced in 
response to multiple stimuli including hypoxia and ischaemic cytokines so it was anticipated that all 
participants would experience an upregulation in HO-1 after transplantation. Nevertheless, HA 
treatment increased macrophage HO-1 more than placebo treatment and reiterated results from 
cellular, pre-clinical and healthy volunteer studies (12-14). Figure 2c confirmed that, as expected, 
there is a distinct peak in protein concentration after each HA infusion with a return to near baseline 
expression 48 hours later. This replicates the findings of previous healthy volunteer studies (14). The 
pattern of mRNA upregulation did not mirror this because although there was a significant peak at 24 
hours, this was not seen again after   the   second   infusion.   This   anomaly  may   be   due   to   the   ΔΔCT 
method used because all samples were referenced to baseline (D0) and it may be more appropriate to 
normalise D3 to D2 to identify a second upregulation. 
 
This is the first clinical study to show that HA treatment increases HO-1 protein immunopositivity 
and the number of HO-1 positive macrophages in renal graft tissue.  Renal HO-1 mRNA did not have 
the same response which may be related to timing of the biopsy. Earlier research has shown that the 
half-life of HO-1 mRNA in vitro renal cells after hemin treatment is only four hours (16) and 
therefore the D5 biopsy may be too late to detect a difference in the more transient mRNA.  
 
The present study was powered for a cellular outcome but given its importance, the study attempted 
to establish whether pre-treatment with HA was associated with a reduction in renal injury or 
function post-transplant. Serum creatinine is an unreliable marker of acute kidney injury and does not 
accurately reflect the degree of damage until it reaches a nadir, which may be several days post-op. 
The urinary biomarkers KIM-1 and NGAL have been validated as independent predictors of graft 
survival after renal transplantation (17, 18). In this study, the maximum NGAL and KIM-1 levels 
were lower after HA treatment on all days indicating reduced renal injury but the differences were 
not statistically significant. There was also no evidence of histological protection after biopsy 
analysis.  
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One of the challenges in clinical trials of renal transplantation is the lack of a single clear definition 
of DGF (19). In  the  present  study  the  ‘functional’  definition  was  used,  defined as increased or stable 
serum creatinine, or a decrease of <10% per day for three consecutive days in the first week after 
transplantation (20). This was preferred over the definition of DGF as the requirement for dialysis 
within the first seven days following transplantation, because the decision to dialyse a patient may be 
subjective with variation in practice between clinicians. Also a recent study found functional DGF 
but not dialysis-defined DGF to be associated independently with subsequent transplant failure (20).  
 
Despite clear evidence that HA upregulated HO-1 in this study, it did not translate into the structural 
or functional cytoprotection seen in pre-clinical and observational studies (12, 21-24). In laboratory 
studies, induction of HO-1 in macrophages (10), and renal tissue (12, 23) offers protection against 
renal IRI and the presence of HO-1 expressing renal macrophages has been shown to safeguard renal 
function in the face of significant structural injury (11). There are a few possible explanations why 
HO-1 upregulation did not confer protection; firstly, there was a modest protection but the sample 
size was too small to detect it. This provisional study was not powered to this endpoint and larger 
studies are required. This is a common issue in renal transplant research and few interventions have 
impacted on DGF rates despite promising pre-clinical results.  
Secondly, two doses of HA were insufficient. Human studies have shown that HO-1 expression 
increases with additional HA doses and more may be required to maximise and sustain the effect on 
macrophages and renal tissue for clinical benefits (14).   
Thirdly, it may be that the equivocal structural and functional results are genuine because HA has 
other effects in clinical IRI that inhibits the anticipated positive consequences of HO-1 upregulation. 
Fourthly, it has also been proposed that the protective response of HO-1 may be limited and 
susceptible to being overwhelmed. It may be that once a level of injury has been reached, further 
HO-1 induction cannot prevent the damage (25). Clinical renal transplantation delivers sizable, 
diverse insults to the kidney, which are not fully modelled in animal experimentation, and may 
explain why preclinical findings do not equate to human studies.  
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Given the unique nature of this study, further research is required to determine whether the amount of 
HO-1 upregulation seen here is sufficient for protection. This study establishes a sound basis for 
undertaking a clinical trial of HA vs. placebo powered to detect clinical differences in graft function 
and this is planned. There is also scope to increase the number of HA infusions within the UK 
prescribing licence and this is also currently under investigation in our centre. HA is a safe 
alternative to hemin because the effects of ferric heme are reduced when hemin is liganded to 
arginine as in HA (26). HA may offer an alternative to other renal transplant conditioning strategies 
that have not fulfilled their potential when translated to clinical studies such as erythropoietin (27, 
28), statins (29) and ischaemic pre-conditioning (30).  HA is well suited for such a trial in renal 
transplant recipients because it was well tolerated and has demonstrated induction of HO-1 in 
PBMCs and renal tissue when administered pre and post-renal transplant surgery.  
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 16 
 
 
Acknowledgements 
 
The HOT study was only possible thanks to the generous funding from NHS Blood and Transplant 
and with help from the laboratory staff at QMRI and staff in the Radiology department, Pathology 
department and the Transplant unit in Royal Infirmary of Edinburgh. The East of Scotland recipient 
transplant coordinators were crucial to the study and our grateful thanks to them. Cat Graham and 
Sharon Harden at University of Edinburgh provided statistical support. 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 17 
References 
1. Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in 
patients listed for transplantation. J Am Soc Nephrol. 2005;16(6):1859-65. 
2. Chatauret N, Badet L, Barrou B, Hauet T. Ischemia-reperfusion: From cell biology to acute 
kidney injury. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe 
francaise d'urologie. 2014;24 Suppl 1:S4-12. 
3. Yarlagadda SG, Coca SG, Formica RN, Jr., Poggio ED, Parikh CR. Association between 
delayed graft function and allograft and patient survival: a systematic review and meta-analysis. 
Nephrol Dial Transplant. 2009;24(3):1039-47. 
4. Selzner N, Boehnert M, Selzner M. Preconditioning, postconditioning, and remote 
conditioning in solid organ transplantation: basic mechanisms and translational applications. 
Transplant Rev (Orlando). 2012;26(2):115-24. 
5. Ferenbach DA, Kluth DC, Hughes J. Hemeoxygenase-1 and renal ischaemia-reperfusion 
injury. Nephron Exp Nephrol. 2010;115(3):e33-7. 
6. Kirkby KA, Adin CA. Products of heme oxygenase and their potential therapeutic 
applications. Am J Physiol Renal Physiol. 2006;290(3):F563-71. 
7. Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and 
other tissues. Kidney Int. 2006;70(3):432-43. 
8. Roach JP, Moore EE, Partrick DA, Damle SS, Silliman CC, McIntyre RC, Jr., et al. Heme 
oxygenase-1 induction in macrophages by a hemoglobin-based oxygen carrier reduces endotoxin-
stimulated cytokine secretion. Shock. 2009;31(3):251-7. 
9. Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, et al. Distinct macrophage 
phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011;22(2):317-26. 
10. Gueler F, Park JK, Rong S, Kirsch T, Lindschau C, Zheng W, et al. Statins attenuate 
ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J 
Pathol. 2007;170(4):1192-9. 
11. Ferenbach DA, Ramdas V, Spencer N, Marson L, Anegon I, Hughes J, et al. Macrophages 
expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol Ther. 
2010;18(9):1706-13. 
12. Ferenbach DA, Nkejabega NC, McKay J, Choudhary AK, Vernon MA, Beesley MF, et al. 
The induction of macrophage hemeoxygenase-1 is protective during acute kidney injury in aging 
mice. Kidney Int. 2011;79(9):966-76. 
13. Bharucha AE, Kulkarni A, Choi KM, Camilleri M, Lempke M, Brunn GJ, et al. First-in-
human study demonstrating pharmacological activation of heme oxygenase-1 in humans. Clin 
Pharmacol Ther. 2010;87(2):187-90. 
14. Doberer D, Haschemi A, Andreas M, Zapf TC, Clive B, Jeitler M, et al. Haem arginate 
infusion stimulates haem oxygenase-1 expression in healthy subjects. Br J Pharmacol. 
2010;161(8):1751-62. 
15. de Almeida MC, Silva AC, Barral A, Barral Netto M. A simple method for human 
peripheral blood monocyte isolation. Memorias do Instituto Oswaldo Cruz. 2000;95(2):221-3. 
16. Hill-Kapturczak N, Sikorski E, Voakes C, Garcia J, Nick HS, Agarwal A. An internal 
enhancer regulates heme- and cadmium-mediated induction of human heme oxygenase-1. Am J 
Physiol Renal Physiol. 2003;285(3):F515-23. 
17. Hollmen ME, Kyllonen LE, Inkinen KA, Lalla ML, Salmela KT. Urine neutrophil 
gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney 
Int. 2011;79(1):89-98. 
18. van Timmeren MM, Vaidya VS, van Ree RM, Oterdoom LH, de Vries AP, Gans RO, et al. 
High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in 
renal transplant recipients. Transplantation. 2007;84(12):1625-30. 
19. Yarlagadda SG, Coca SG, Garg AX, Doshi M, Poggio E, Marcus RJ, et al. Marked 
variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol 
Dial Transplant. 2008;23(9):2995-3003. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 18 
20. Sharif A, Borrows R. Delayed graft function after kidney transplantation: the clinical 
perspective. Am J Kidney Dis. 2013;62(1):150-8. 
21. Blydt-Hansen TD, Katori M, Lassman C, Ke B, Coito AJ, Iyer S, et al. Gene transfer-
induced local heme oxygenase-1 overexpression protects rat kidney transplants from 
ischemia/reperfusion injury. J Am Soc Nephrol. 2003;14(3):745-54. 
22. Lemos FB, Ijzermans JN, Zondervan PE, Peeters AM, van den Engel S, Mol WM, et al. 
Differential expression of heme oxygenase-1 and vascular endothelial growth factor in cadaveric 
and living donor kidneys after ischemia-reperfusion. J Am Soc Nephrol. 2003;14(12):3278-87. 
23. Tullius SG, Nieminen-Kelha M, Buelow R, Reutzel-Selke A, Martins PN, Pratschke J, et 
al. Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor 
treatment with cobalt-protoporphyrin for the induction of heme oxygenase-1. Transplantation. 
2002;74(5):591-8. 
24. Ollinger R, Kogler P, Biebl M, Sieb M, Sucher R, Bosmuller C, et al. Protein levels of 
heme oxygenase-1 during reperfusion in human kidney transplants with delayed graft function. 
Clin Transplant. 2008;22(4):418-23. 
25. Tsuchihashi S, Livhits M, Zhai Y, Busuttil RW, Araujo JA, Kupiec-Weglinski JW. Basal 
rather than induced heme oxygenase-1 levels are crucial in the antioxidant cytoprotection. J 
Immunol. 2006;177(7):4749-57. 
26. Tenhunen R, Tokola O, Linden IB. Haem arginate: a new stable haem compound. The 
Journal of pharmacy and pharmacology. 1987;39(10):780-6. 
27. Martinez F, Kamar N, Pallet N, Lang P, Durrbach A, Lebranchu Y, et al. High dose epoetin 
beta in the first weeks following renal transplantation and delayed graft function: Results of the 
Neo-PDGF Study. Am J Transplant. 2010;10(7):1695-700. 
28. Aydin Z, Mallat MJ, Schaapherder AF, van Zonneveld AJ, van Kooten C, Rabelink TJ, et 
al. Randomized trial of short-course high-dose erythropoietin in donation after cardiac death 
kidney transplant recipients. Am J Transplant. 2012;12(7):1793-800. 
29. Fellstrom B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of 
fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. 
Kidney Int. 2004;66(4):1549-55. 
30. Huang Y, Shan J, Wang C, Ma J, Li D, Li L, et al. Can ischemic preconditioning alone 
really protect organs from ischemia reperfusion injury in transplantation. Transplant immunology. 
2009;20(3):127-31. 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Tables for HOT document  
Table 1. Baseline characteristics of the 40 randomised participants by treatment group 
Characteristic Placebo (n=19) HA (n=21) 
Mean age (range) 52.4 (25- 79) 52.1 (21- 69) 
Male (%) 11 (58) 12 (57) 
1st transplant (%) 19 (100) 20 (95) 
2nd transplant (%) 0 1 (5) 
Dialysis patient (%) 17 (89) 20 (95) 
Drug history; Statin (%) 11 (58) 13 (62) 
Drug history; any type antiplatelet agent (%) 8 (39) 6 (29) 
Time from infusion to reperfusion in 
minutes (range) 
420.6  
(39.0- 1586.0) 
249.0  
(48.0- 803.0) 
 
Donor characteristics   
Mean age (range) 45.2 (21- 73) 46.8 (14- 69) 
Male (%) 13 (72) 10 (53) 
DBD (%) 9 (50) 9 (47) 
Mode of organ perfusion- hypothermic (%) 3 (17) 2 (11) 
Mode of organ perfusion- cold static (%) 15 (83) 17 (89) 
HLA match  
0 HLA-DRB1 mismatch 
1 HLA- DRB1 mismatch 
2 HLA-DRB1 mismatch 
 
3 (17) 
9 (50) 
6 (33) 
 
1 (5) 
13 (69) 
5 (27) 
Number with virtual crossmatch1 12 (67) 15 (79) 
Mean CIT in minutes2 (range) 691.7  
(351- 1287) 
731.5  
(450- 1213) 
Mean WIT in minutes3 (range) 36.2 (28- 61) 37.6 (23- 59) 
Mean values are given for continuous variables, while numbers of patients (percentages) are given otherwise.  
1Virtual crossmatch= crossmatch that is performed before the organ arrives at RIE. This reduces the ischaemic 
time  and  is  possible  when  the  recipient’s  antibody  specificities  have  been  identified  and  the  donor  HLA  type  is  
known. 
2CIT= Cold ischaemic time= time from storage in ice at recovery to removal from ice during transplant 
operation 
3WIT= Warm ischaemic time (2nd)= time from removal from ice for transplant to reperfusion  
7DEOH
 Figure legends for HOT_article document 
 
Figure 1. Flow chart showing recruitment and study characteristics  
 
Figure 2: Treatment with HA upregulated HO-1 protein and mRNA expression in 
peripheral blood mononuclear cells (PBMCs).  
a) HO-1 protein upregulation: expressed as the difference in HO-1 expression on D1 
compared with D0. HA upregulated HO-1 expression by 11.1ng/ml [1.0- 37.0], compared 
with placebo -0.14ng/ml [-0.7- 0.3]; p<0.0001(n=36, 1 sample could not be analysed). b) HA 
upregulated HO-1 mRNA expression 2.73 fold [1.8- 3.2] compared with placebo 1.41 fold 
[1.2- 2.2]; p=0.02 (n=37). c) Change in PBMC HO-1 protein expression over 5 days, 
demonstrating significantly increased HO-1 expression on D1 and D3 after HA treatment 
(p<0.005). d) Change in HO-1 mRNA expression over 5 days, expressed as fold increase 
compared with D0. No significant difference at D5. 
 
Figure 3: There was significant upregulation of HO-1 expression in CD68-positive 
macrophages after HA treatment compared with placebo at day 5. 
a) Number of CD68-positive macrophages at D0 and D5 with HA treatment compared with 
placebo: D0 p=0.956, D5 p=0.13 (n=21, some tissue not suitable for staining). b) Percentage 
CD68-positive macrophages expressing HO-1 at D0 and D5 with HA compared with 
placebo. At D5, HA: 50.81 cells per hpf [40.0- 59.8], placebo: 22.3 [0- 34.8]; p=0.012 (n=21) 
c) Dual stain immunofluorescent images of renal tissue (green: CD68, red: HO-1, blue: 
nuclear marker), white arrows highlight dual positive cells from D0 HA d) D0 placebo e) D5 
HA and f) D5 placebo (x20 magnification) 
 
Figure 4:  HO-1 protein but not mRNA was upregulated in renal tissue. 
 
a) HO-1 protein upregulation: expressed as the difference in % HO-1 expression on D5 
compared with D0, HA upregulated protein by 0.21% [0.1- 0.6] compared to placebo of -
0.03% [-1.3- 0.1], p= 0.017 (n=22, three samples insufficient for protein analysis).  
)LJXUHOHJHQGV
 b) HO-1 mRNA upregulation at D5 expressed as fold increase from D0 showed no significant 
difference between the groups p=0.45 (n=25). Images of immunohistological staining for HO-1 
(DAB) in renal tissue at c) D0 HA, d) D0 placebo, e) D5 HA and f) D5 placebo (x20 
magnification)   
 
Figure 5: Change in urinary biomarkers over 5 days after HA treatment and placebo.  
There was no significant difference between the HA and placebo treatment at any time point in 
a) KIM-1 and b) NGAL-1. All p-values = >0.05. 
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CONSORT!2010!Flow!Diagram!for!HOT!study!!
Assessed for eligibility (n= 76) 
Excluded  (n= 36) 
♦!!!Not meeting inclusion criteria (n= 14) 
♦!!!Declined to participate (n= 8) 
♦!!!Other reasons (n=14) 
Analysed  (n= 18) 
♦!Excluded from analysis (n= 0)!
Lost to follow-up (n= 0) 
Discontinued intervention (n= 1), pt declined 
2nd dose 
Allocated to placebo intervention (n=19) 
♦!Received allocated intervention (n= 18)!
♦!Did not receive allocated intervention  (n= 1), 
organ not suitable for transplant!
Lost to follow-up (n= 0) 
Discontinued intervention (n= 1), pt declined 
2nd dose 
 
Allocated to active intervention (n= 21) 
♦!Received allocated intervention (n= 19)!
♦!Did not receive allocated intervention  (n= 2) 
      organs not suitable for transplant!
Analysed  (n=19) 
♦!Excluded from analysis (n= 0)!
!
Allocation)
Analysis)
Follow.Up)
Randomized (n= 40) 
Enrollment)
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